Celgene Corporation Company Profile (NASDAQ:CELG)

About Celgene Corporation (NASDAQ:CELG)

Celgene Corporation logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CELG
  • CUSIP: 15102010
  • Web: www.celgene.com
Capitalization:
  • Market Cap: $99.81 billion
  • Outstanding Shares: 782,350,000
Average Prices:
  • 50 Day Moving Avg: $134.04
  • 200 Day Moving Avg: $124.79
  • 52 Week Range: $96.93 - $139.00
P/E:
  • Trailing P/E Ratio: 39.51
  • Foreward P/E Ratio: 14.32
  • P/E Growth: 0.82
Sales & Book Value:
  • Annual Revenue: $12.19 billion
  • Price / Sales: 8.19
  • Book Value: $10.80 per share
  • Price / Book: 11.81
Profitability:
  • EBIDTA: $4.83 billion
  • Net Margins: 21.35%
  • Return on Equity: 68.51%
  • Return on Assets: 17.04%
Debt:
  • Debt-to-Equity Ratio: 1.63%
  • Current Ratio: 4.05%
  • Quick Ratio: 3.89%
Misc:
  • Average Volume: 3.92 million shs.
  • Beta: 1.89
  • Short Ratio: 2.24
 

Frequently Asked Questions for Celgene Corporation (NASDAQ:CELG)

What is Celgene Corporation's stock symbol?

Celgene Corporation trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene Corporation's stock split? How did Celgene Corporation's stock split work?

Celgene Corporation shares split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were issued to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene Corporation stock prior to the split would have 200 shares after the split.

How were Celgene Corporation's earnings last quarter?

Celgene Corporation (NASDAQ:CELG) issued its quarterly earnings results on Thursday, July, 27th. The company reported $1.82 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.61 by $0.21. The company earned $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company's revenue for the quarter was up 18.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.44 earnings per share. View Celgene Corporation's Earnings History.

When will Celgene Corporation make its next earnings announcement?

Celgene Corporation is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Celgene Corporation.

What guidance has Celgene Corporation issued on next quarter's earnings?

Celgene Corporation updated its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $7.25-7.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.29. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.19 billion.

Where is Celgene Corporation's stock going? Where will Celgene Corporation's stock price be in 2017?

26 analysts have issued 1 year price objectives for Celgene Corporation's stock. Their predictions range from $98.00 to $175.00. On average, they anticipate Celgene Corporation's stock price to reach $147.07 in the next year. View Analyst Ratings for Celgene Corporation.

What are analysts saying about Celgene Corporation stock?

Here are some recent quotes from research analysts about Celgene Corporation stock:

  • 1. Cann analysts commented, "Celgene announced that Idhifa (enasidenib/AG-221) was granted approval from FDA for the treatment of adult patients with relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test. It was reported that FDA approval was based on the clinical data from an open-label, single-arm, multicenter, two-cohort clinical trial of adult patients with relapsed or refractory AML with an IDH2 mutation (Study AG221-C-001, NCT01915498). Idhifa was approved concurrently with the Abbott RealTime IDH2 companion diagnostic test, which is FDA-approved as an aid in identifying AML patients for treatment with Idhifa." (8/1/2017)
  • 2. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration. Celgene continues to progress with its label expansion efforts and pipeline development. Revlimid was approved as a single agent for maintenance therapy in adult patients with NDMM following ASCT both in the U.S. and EU. Celgene’s NDA for Idhifa for relapsed and/or refractory acute myeloid leukemia was granted Priority Review with a PDUFA action date of Aug 30, 2017. Label expansion of drugs would boost revenues significantly. Moreover, shares of Celgene have outperformed the industry in the past one year. However, Celgene is highly dependent on Revlimid. Otezla sales in the first quarter were impacted by managed care dynamics that drove lower total marketplace prescriptions for psoriasis therapies although the pressure should ease as the year goes." (7/19/2017)
  • 3. Cantor Fitzgerald analysts commented, "Acquisition of worldwide Rights to BeiGene,s (NASDAQ: BGNE, NC) excluding Asia, PD-1 inhibitor for solid tumors, BGB-A317, enhances CELG’s oncology portfolio and augments its immuno-oncology efforts." (7/6/2017)

Who are some of Celgene Corporation's key competitors?

Who are Celgene Corporation's key executives?

Celgene Corporation's management team includes the folowing people:

  • Robert J. Hugin, Executive Chairman of the Board
  • Scott A. Smith, President, Chief Operating Officer
  • Mark J. Alles, Chief Executive Officer, Director
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President
  • Terrie Curran, President, Global Inflammation & Immunology Franchise
  • Michael F. Pehl, President, Hematology & Oncology
  • Rupert J. Vessey, President - Research and Early Development
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary
  • Michael D. Casey, Lead Independent Director
  • Michael W. Bonney, Director

Who owns Celgene Corporation stock?

Celgene Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.25%), Vanguard Group Inc. (6.84%), State Street Corp (4.14%), Jennison Associates LLC (1.71%), FMR LLC (1.61%) and Franklin Resources Inc. (1.42%). Company insiders that own Celgene Corporation stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin and Rupert Vessey. View Institutional Ownership Trends for Celgene Corporation.

Who sold Celgene Corporation stock? Who is selling Celgene Corporation stock?

Celgene Corporation's stock was sold by a variety of institutional investors in the last quarter, including Orbis Allan Gray Ltd, Old Mutual Global Investors UK Ltd., Winslow Capital Management LLC, Jackson Square Partners LLC, Bank of New York Mellon Corp, Geneva Advisors LLC, APG Asset Management N.V. and Macquarie Group Ltd.. Company insiders that have sold Celgene Corporation stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin and Rupert Vessey. View Insider Buying and Selling for Celgene Corporation.

Who bought Celgene Corporation stock? Who is buying Celgene Corporation stock?

Celgene Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., Oaktop Capital Management II L.P., Arrowstreet Capital Limited Partnership, Vanguard Group Inc., Harbour Capital Advisors LLC, Renaissance Technologies LLC and UBS Asset Management Americas Inc.. Company insiders that have bought Celgene Corporation stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene Corporation.

How do I buy Celgene Corporation stock?

Shares of Celgene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene Corporation's stock price today?

One share of Celgene Corporation stock can currently be purchased for approximately $127.58.


MarketBeat Community Rating for Celgene Corporation (NASDAQ CELG)
Community Ranking:  4.0 out of 5 (   )
Outperform Votes:  1,537 (Vote Outperform)
Underperform Votes:  370 (Vote Underperform)
Total Votes:  1,907
MarketBeat's community ratings are surveys of what our community members think about Celgene Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celgene Corporation (NASDAQ:CELG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 21 Buy Ratings
Consensus Rating:Buy (Score: 2.77)
Consensus Price Target: $147.07 (15.28% upside)

Analysts' Ratings History for Celgene Corporation (NASDAQ:CELG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$175.00MediumView Rating Details
8/1/2017CannReiterated RatingBuy$175.00LowView Rating Details
7/31/2017Jefferies Group LLCReiterated RatingBuy$160.00LowView Rating Details
7/31/2017ArgusUpgradeHold -> Buy$96.93 -> $160.00LowView Rating Details
7/28/2017Barclays PLCReiterated RatingHold$135.00LowView Rating Details
7/28/2017BMO Capital MarketsReiterated RatingOutperform$152.00 -> $160.00LowView Rating Details
7/28/2017Leerink SwannReiterated RatingOutperform$150.00 -> $160.00LowView Rating Details
7/27/2017Canaccord GenuitySet Price TargetBuy$156.00LowView Rating Details
7/28/2017Stifel NicolausInitiated CoverageBuy$155.00LowView Rating Details
7/27/2017Cowen and CompanyReiterated RatingOutperform$150.00LowView Rating Details
7/27/2017Cantor FitzgeraldSet Price TargetBuy$160.00MediumView Rating Details
7/26/2017MizuhoSet Price TargetBuy$134.00HighView Rating Details
7/21/2017Robert W. BairdReiterated RatingOutperform$162.00LowView Rating Details
7/14/2017SunTrust Banks, Inc.Reiterated RatingBuy$150.00LowView Rating Details
7/10/2017Bank of America CorporationReiterated RatingBuy$153.00LowView Rating Details
7/6/2017Credit Suisse GroupSet Price TargetBuy$148.00LowView Rating Details
6/30/2017BTIG ResearchDowngradeBuy -> Neutral$96.93 -> $131.70LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformLowView Rating Details
5/24/2017J P Morgan Chase & CoReiterated RatingBuyLowView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSell$93.00 -> $98.00LowView Rating Details
1/27/2017Morgan StanleyLower Price TargetEqual Weight$120.00 -> $117.00N/AView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
12/4/2016Royal Bank Of CanadaReiterated RatingOutperformN/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
10/18/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
9/29/2016Citigroup Inc.Boost Price TargetBuy$124.00 -> $127.00N/AView Rating Details
7/6/2016JMP SecuritiesReiterated RatingBuy$152.00N/AView Rating Details
4/28/2016Raymond James Financial, Inc.Reiterated RatingBuyN/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingOutperformN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralN/AView Rating Details
(Data available from 8/17/2015 forward)

Earnings

Earnings History for Celgene Corporation (NASDAQ:CELG)
Earnings by Quarter for Celgene Corporation (NASDAQ:CELG)
Earnings History by Quarter for Celgene Corporation (NASDAQ CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$1.89N/AView Earnings Details
7/27/20176/30/2017$1.61$1.82$3.23 billion$3.27 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celgene Corporation (NASDAQ:CELG)
2017 EPS Consensus Estimate: $6.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.44$1.46$1.45
Q2 20173$1.61$1.68$1.64
Q3 20173$1.68$1.77$1.72
Q4 20173$1.72$1.84$1.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene Corporation (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celgene Corporation (NASDAQ:CELG)
Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 78.34%
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2017Ernest MarioDirectorSell18,506$130.52$2,415,403.12View SEC Filing  
8/2/2017Gilla KaplanDirectorSell7,500$134.52$1,008,900.00View SEC Filing  
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.00View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.00View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.80View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.50View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.30View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.00View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.39View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.00View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.56View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.00View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.40View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celgene Corporation (NASDAQ:CELG)
Latest Headlines for Celgene Corporation (NASDAQ:CELG)
Source:
DateHeadline
finance.yahoo.com logoStock Losses Top 1%; These Stocks Hit Sell Signals
finance.yahoo.com - August 17 at 6:23 PM
fool.com logoThe 3 Best Stocks in Healthcare
www.fool.com - August 17 at 9:32 AM
fool.com logoWhy I Love Celgene Corporation -- The Motley Fool - Motley Fool
www.fool.com - August 15 at 10:53 PM
americanbankingnews.com logoCelgene Corporation (CELG) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 15 at 4:36 PM
fool.com logoWhy I Love Celgene Corporation
www.fool.com - August 15 at 8:23 AM
finance.yahoo.com logo3 Stocks for Retirees to Grow Their Nest Egg
finance.yahoo.com - August 14 at 10:31 PM
americanbankingnews.com logoErnest Mario Sells 18,506 Shares of Celgene Corporation (CELG) Stock
www.americanbankingnews.com - August 14 at 10:31 PM
businesswire.com logoSage Bionetworks and Celgene Corporation Announce the Launch of Journey PRO, a Mobile Health Research Study ... - Business Wire (press release)
www.businesswire.com - August 14 at 5:27 PM
finance.yahoo.com logoETFs with exposure to Celgene Corp. : August 14, 2017
finance.yahoo.com - August 14 at 5:27 PM
finance.yahoo.com logoIHS Markit Score downgrades Celgene Corp to 60 out of 100, ranking positively in only one out of three available IHS Markit categories.
finance.yahoo.com - August 11 at 10:34 PM
finance.yahoo.com logoOzanimod Could Drive Celgene’s Long-Term Growth
finance.yahoo.com - August 11 at 10:34 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Celgene Corp.
finance.yahoo.com - August 11 at 10:34 PM
nasdaq.com logoFcg Advisors, Llc Buys Celgene Corp, Guggenheim BulletShares 2019 Corporate Bond, PowerShares ... - Nasdaq
www.nasdaq.com - August 11 at 5:30 PM
finance.yahoo.com logoCelgene Corp. breached its 50 day moving average in a Bearish Manner : CELG-US : August 11, 2017
finance.yahoo.com - August 11 at 5:30 PM
seekingalpha.com logoCelgene slips 3% on modified oncology deal with Sutro - Celgene ... - Seeking Alpha
seekingalpha.com - August 11 at 4:19 AM
americanbankingnews.com logoCelgene Corporation (NASDAQ:CELG) Lifted to "Strong-Buy" at Vetr Inc.
www.americanbankingnews.com - August 11 at 12:38 AM
seekingalpha.com logoA Celgene-Ius Investment
seekingalpha.com - August 10 at 6:16 PM
finance.yahoo.com logo[$$] Sutro Biopharma Reworks Immuno-Oncology Alliance With Celgene
finance.yahoo.com - August 10 at 6:16 PM
finance.yahoo.com logoHow 2 biotech partners reimagined cancer pact — and made it work again for both
finance.yahoo.com - August 10 at 6:16 PM
finance.yahoo.com logoMajor Biotechs Send Short Sellers Running for Cover
finance.yahoo.com - August 10 at 6:16 PM
finance.yahoo.com logoCelgene’s Abraxane Continued Steady Growth in 2Q17
finance.yahoo.com - August 10 at 6:16 PM
seekingalpha.com logoCelgene slips 3% on modified oncology deal with Sutro
seekingalpha.com - August 10 at 1:57 PM
finance.yahoo.com logoBiotech Breakouts Suggest It Is Time to Buy
finance.yahoo.com - August 9 at 5:16 PM
finance.yahoo.com logoCelgene’s Revlimid Witnessed High Growth in 2Q17
finance.yahoo.com - August 9 at 5:16 PM
fool.com logoWhy BeiGene Soared 56.6% In July
www.fool.com - August 9 at 8:15 AM
bizjournals.com logoHawaii to receive $477000 from drug manufacturer settlement - Pacific Business News (Honolulu)
www.bizjournals.com - August 8 at 4:50 PM
bizjournals.com logoHawaii to receive $477000 from drug manufacturer settlement - Pacific Business News (Honolulu)
www.bizjournals.com - August 8 at 4:50 PM
seekingalpha.com logoCelgene Paves The Way For Rare AML Patients - Seeking Alpha
seekingalpha.com - August 7 at 10:32 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Celgene Corporation (NASDAQ:CELG) Will Post Quarterly Sales of $3.44 Billion
www.americanbankingnews.com - August 6 at 7:11 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: August 5, 2017
seekingalpha.com - August 5 at 4:33 PM
fool.com logoCelgene vs. Gilead Sciences: Who Reported Better Earnings? - Motley Fool
www.fool.com - August 5 at 3:23 AM
finance.yahoo.com logoOp-Ed: Getting patients access to 'precision' medicines is crucial
finance.yahoo.com - August 4 at 5:21 PM
finance.yahoo.com logoCelgene vs. Gilead Sciences: Who Reported Better Earnings?
finance.yahoo.com - August 4 at 5:20 PM
americanbankingnews.com logoCelgene Corporation (NASDAQ:CELG) Expected to Announce Earnings of $1.72 Per Share
www.americanbankingnews.com - August 4 at 4:39 PM
americanbankingnews.com logoGilla Kaplan Sells 7,500 Shares of Celgene Corporation (CELG) Stock
www.americanbankingnews.com - August 3 at 7:50 PM
finance.yahoo.com logoCelgene CEO: Time to think about health care in a differe...
finance.yahoo.com - August 3 at 6:35 PM
finance.yahoo.com logoLooking to Buy Some Celgene? Now's a Good Time
finance.yahoo.com - August 3 at 6:35 PM
cnbc.com logoOp-Ed: Getting patients access to 'precision' medicines is crucial
www.cnbc.com - August 3 at 6:58 AM
fool.com logo3 Reasons the Best Is Yet to Come for Celgene
www.fool.com - August 2 at 10:39 PM
americanbankingnews.com logoCelgene Corporation (NASDAQ:CELG) Given Buy Rating at Cann
www.americanbankingnews.com - August 1 at 4:38 PM
reuters.com logoFDA approves leukemia treatment developed by Celgene, Agios - Reuters
www.reuters.com - August 1 at 3:36 PM
investorplace.com logoTrade of the Day: Celgene Corporation (CELG) - Investorplace.com
investorplace.com - August 1 at 3:36 PM
finance.yahoo.com logoCelgene Corporation -- Moody's assigns Baa2 to Celgene's notes; stable outlook
finance.yahoo.com - August 1 at 3:36 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Bank of America, UnitedHealth, Intel, UPS and Celgene
finance.yahoo.com - August 1 at 3:36 PM
finance.yahoo.com logoFDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation
finance.yahoo.com - August 1 at 3:35 PM
finance.yahoo.com logoFDA approves leukemia treatment developed by Celgene, Agios
finance.yahoo.com - August 1 at 3:35 PM
investorplace.com logoTrade of the Day: Celgene Corporation (CELG)
investorplace.com - August 1 at 9:20 AM
finance.yahoo.com logoTop Analyst Reports for Bank of America, UnitedHealth, Intel & Celgene
finance.yahoo.com - August 1 at 3:07 AM
americanbankingnews.com logoCelgene Corporation (CELG) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - July 31 at 7:56 PM
finance.yahoo.com logoThe Celgene Story Is Bigger Than Revlimid Now; Argus Upgrades
finance.yahoo.com - July 31 at 5:02 PM

Social

Chart

Celgene Corporation (CELG) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by MarketBeat.com Staff